MAPT and Alzheimer disease: Depending on the prevalence of AD as well as that of other diseases modifying CSF amyloid and tau concentrations in a cohort, the reduction in the need for LP could be well over 50%, significantly reducing the cost of management of these patients and limiting invasive and unnecessary medical procedures.